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To the Editors,
Sexual dysfunction is a frequently reported side effect of antidepressants, which negatively influences quality of life and adherence to medication .
With interest we read the study of who reported a low incidence of treatment-emergent sexual dysfunction (TESD) in patients treated with vortioxetine. In their analysis of 11 randomized placebo-controlled short-term treatment studies for major depressive disorder (MDD), they report 1.6-1.8% TESD for vortioxetine 5-20 mg versus 1.0% for placebo, 12.4% for venlafaxine 225 mg and 4.5% for duloxetine 60 mg. In an additional analysis on four studies on generalized anxiety disorder (GAD), TESD was 2.6-3.2% for vortioxetine 5-10 mg, 0.7% for placebo and 11.0% for duloxetine 60 mg. These results were based on spontaneous reports of patients. The authors conclude that TESD in patients treated with vortioxetine is not different from placebo, and therefore has a beneficial profile in this domain.
When interpreting these results, it should be noted that, in contrast to many other side effects, sexual dysfunction is rarely spontaneously reported, leading to an underestimation of its prevalence and contributing to decreased adherence to treatment (de Boer et al., 2015) . Interestingly, the difference between the use of spontaneous reports versus a validated questionnaire has already been investigated in patients using vortioxetine by Jacobsen et al. (2015b) . In a pooled analysis of six MDD studies and one GAD study, all of which were also included in the review of Baldwin et al., TESD was reported spontaneously in 2.2% of vortioxetine-treated patients. In these seven studies, however, sexual dysfunction was also measured using the Arizona Sexual Experience Scale (ASEX), a validated questionnaire. In 1115 patients who did not report sexual dysfunction according to the ASEX at baseline, the rates of TESD were 25.7% for vortioxetine 5 mg, 35.3% for vortioxetine 10 mg, 42.9% for vortioxetine 15 mg, 46.1% for vortioxetine 20 mg, 32.0% for placebo and 48.2% for duloxetine. Although the incidence of TESD increased with vortioxetine dose there was no statistically significant higher risk of developing TESD versus placebo. Higher TESD risk was reported for duloxetine 60 mg/ day versus placebo and versus vortioxetine 5 or 10 mg while no significant difference was determined between duloxetine 60 mg/day versus vortioxetine 15 or 20 mg.
When comparing the papers of and Jacobsen et al. (2015b) that partially describe the same original studies, it again becomes clear that TESD is reported far more frequently when using a validated questionnaire versus spontaneous reports. Only reporting spontaneously mentioned sexual side effects may be less helpful for clinicians who together with their patients choose between different antidepressants based on side effect profiles reported in the literature.
The publication from also states that vortioxetine is superior to escitalopram in improving TESD. This is based on another study by Jacobsen et al. (2015a) who investigated the effect of vortioxetine versus escitalopram on sexual functioning in adults with well-treated MDD who were experiencing SSRI-induced sexual dysfunction. Participants who had responded to, and were still treated with, citalopram, paroxetine or sertraline were randomized to switch to either vortioxetine 10-20 mg or escitalopram 10-20 mg. Sexual function was assessed using the Changes in Sexual Functioning Questionnaire (CSFQ-14), a validated questionnaire. Patients using vortioxetine showed significantly greater improvements in CSFQ-14 total score (8.8 ± 0.64, mean ± standard error) versus escitalopram (6.6 ± 0.64; p = 0.013), which was the primary outcome. A clinically relevant response, however, was defined as an increase from baseline in CSFQ-14 total score of Journal of Psychopharmacology 31 (3) at least 3 points, which was achieved by 74.7% of patients using vortioxetine versus 66.2% of patients using escitalopram (p = 0.057). Normal sexual functioning at the end of the treatment period (defined as CSFQ-14 score greater than 41 for women and greater than 47 for men) was achieved by 52.1% of patients treated with vortioxetine and 44.2% of patients treated with escitalopram but this difference was not statistically different (p = 0.112).
In conclusion, it may be difficult for interested readers to exactly determine the possible clinical benefit of vortioxetine on sexual functioning. First, data on TESD are available. In studies using a validated questionnaire, TESD is lower in patients using vortioxetine 5-10 mg than duloxetine 60 mg, while no difference was found between vortioxetine 15-20 mg and duloxetine 60 mg. No difference in TESD was found between low dosages of vortioxetine versus placebo, while higher doses of vortioxetine are associated with more TESD than placebo. No reliable results are available on TESD in patients using vortioxetine versus antidepressants other than duloxetine. Second, vortioxetine has been investigated for treatment of SSRI-induced sexual dysfunction. Based on the primary outcome, switching to vortioxetine had better results than switching to escitalopram, but when looking at the other outcomes, the exact clinical benefit of vortioxetine in this context is not totally clear.
In order to help readers interpret the real-world meaning of such findings, a critical appraisal of the literature is necessary, focusing on measuring instruments, data analysis and the way results are reported. About measuring instruments, we would argue that a validated questionnaire be used to assess sexual dysfunction in clinical studies, in line with a recent discussion by Khin et al. on regulatory and scientific issues in studies to evaluate sexual dysfunction in antidepressant drug trials (Khin et al., 2015) .
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Reply

David Baldwin
The principal point raised by de Boer and Schoevers is familiar and widely accepted (e.g. Baldwin et al., 2015; Clayton et al., 2016) : that is, the reported rate of treatment-emergent sexual dysfunction during antidepressant treatment varies with the exhaustiveness of the method of enquiry (Baldwin, 2001) . The findings relating to tolerability in our analysis of the large clinical trial database are based on open and non-leading questions to patients, the spontaneous reports of patients, and the observations of study investigators . de Boer and Schoevers are correct in stating there have been additional investigations of the effects of vortioxetine on sexual functioning, which employed other methods for ascertaining the incidence of treatmentemergent sexual side effects: and these smaller studies probably provide a more nuanced estimate of the effects of vortioxetine on sexual functioning and satisfaction. But the most comprehensive analysis, which takes into account the presence of sexual dysfunction at baseline, indicates that the incidence of treatment-emergent sexual dysfunction with vortioxetine was not significantly different from placebo, during short-term treatment of patients with major depression or generalized anxiety disorder (Jacobsen et al., 2016) .
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